The drug would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the FDA’s approval was based on trials which extended median progression-free survival (PFS) by nearly nine months.
Tag Archive for: Tagrisso
AstraZeneca on Thursday released its fourth-quarter and full-year financial results, touting 6% total revenue growth for 2023 even as its COVID-19 business plummeted by more than 90%.
The drug would be used to treat adults with a type of advanced lung cancer, AstraZeneca said, adding that the decision from the regulator was based on a late-stage trial which extended median progression-free survival (PFS) by nearly nine months.
For AstraZeneca, the approval of Enhertu last year marked one of the high points in the company’s scientific program.
J&J’s therapy combination of antibody treatment Rybrevant and experimental drug lazertinib showed a clinically meaningful improvement in progression-free survival rate in patients.
Data released today by AstraZeneca from a late-stage trial combining its blockbuster cancer drug Tagrisso with chemotherapy to treat a type of lung cancer raises the bar for Johnson & Johnson’s rival treatment, analysts said.
J&J’s therapy was tested in patients in whom the disease progressed even after they were treated with AstraZeneca’s Tagrisso.
The latest data, presented at the American Society of Clinical Oncology (ASCO) meeting, establishes Tagrisso as the backbone treatment for EGFR-mutated lung cancer.
Thursday, AstraZeneca reported data from the Phase III ADAURA trial showing its Tagrisso (osimertinib) boosts overall survival (OS) as an adjuvant treatment for early non-small cell lung cancer (NSCLC) after curative resection.
Through ongoing collaboration, new companion diagnostic aims to deliver next-generation sequencing results in as little as 24 hours to help advance precision oncology.
